Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.
2.
Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.
3.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
4.
Novel Drugs Boost Immunotherapy Activity in Resectable Lung Cancer
5.
The self-sacrificing nature of breast cancer cells has been identified as a possible reason for relapse.
1.
Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment
2.
Exploring the Potential of Cytologic Atypia in Cancer Diagnosis
3.
Bispecific Antibodies in DLBCL & Myeloma: Clinical Insights for Physicians
4.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
5.
Targeting Oncology: Expanding Combinatorial Strategies by 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation